CARVEDILOL ( DrugBank: Carvedilol )


4 diseases
告示番号疾患名(ページ内リンク)臨床試験数
57特発性拡張型心筋症1
86肺動脈性肺高血圧症6
113筋ジストロフィー4
210単心室症1

57. 特発性拡張型心筋症


臨床試験数 : 11 薬物数 : 23 - (DrugBank : 12) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 35
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01798992
(ClinicalTrials.gov)
September 200022/2/2013Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human HeartBeta-blocker Effect on Structural Remodeling and Gene Expression in the Failing Human HeartIdiopathic Dilated CardiomyopathyDrug: Carvedilol;Drug: Metoprolol succinate;Drug: Metoprolol succinate + doxazosinUniversity of Colorado, DenverNational Heart, Lung, and Blood Institute (NHLBI);GlaxoSmithKline;AstraZenecaCompleted18 YearsN/AAll56Phase 4United States

86. 肺動脈性肺高血圧症


臨床試験数 : 1,205 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02507011
(ClinicalTrials.gov)
January 31, 201622/7/2015Beta-blockers in Pulmonary Arterial HypertensionBeta-blockers in Pulmonary Arterial Hypertension - A Phase 2 Double-Blind, Placebo-Controlled, Crossover Study Evaluating the Efficacy, and Safety of Carvedilol for Right Ventricular Dysfunction in Pulmonary Arterial HypertensionPulmonary Arterial HypertensionDrug: Carvedilol;Drug: PlaceboUniversity of MinnesotaNULLTerminated18 YearsN/AAll2Phase 2United States
2NCT02120339
(ClinicalTrials.gov)
May 201417/4/2014Carvedilol PAH A Pilot Study of Efficacy and SafetyBeta Blockers in Pulmonary Arterial Hypertension (PAH) A Pilot Study of Efficacy and SafetyPulmonary Hypertension;Cardiac MRI <40Drug: CarvedilolUniversity of MinnesotaNULLTerminated18 Years99 YearsAll5Phase 1United States
3NCT01586156
(ClinicalTrials.gov)
December 201223/4/2012PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol)Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart FailurePulmonary HypertensionDrug: Carvedilol;Drug: placeboThe Cleveland ClinicNational Institutes of Health (NIH);National Heart, Lung, and Blood Institute (NHLBI)Completed18 Years65 YearsAll30N/AUnited States
4NCT01723371
(ClinicalTrials.gov)
September 201231/10/2012Beta Blockers for Treatment of Pulmonary Arterial Hypertension in ChildrenBeta Blockers for Treatment of Pulmonary Arterial Hypertension in ChildrenPulmonary Arterial HypertensionDrug: CarvedilolThe Hospital for Sick ChildrenNULLWithdrawn8 Years17 YearsBoth0Phase 1/Phase 2Canada
5NCT00964678
(ClinicalTrials.gov)
June 201024/8/2009Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial HypertensionPilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial HypertensionPulmonary Arterial HypertensionDrug: CarvedilolVirginia Commonwealth UniversityGlaxoSmithKlineCompleted18 YearsN/AAll10Phase 1/Phase 2United States
6NCT00240656
(ClinicalTrials.gov)
October 200517/10/2005Spironolactone Combined With Captopril and Carvedilol for the Treatment of Pulmonary Arterial HypertensionOfficial Title: Spironolactone Combined With Captopril and Carvedilol for the Treatment of Patients With Pulmonary Arterial Hypertension Associated With Congenital Heart Disease—Focus on Pulmonary Artery RemodelingHypertension, PulmonaryDrug: spironolactone captopril carvedilolHebei Medical UniversityNULLCompletedN/A80 YearsBothPhase 1China

113. 筋ジストロフィー


臨床試験数 : 646 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2008-007236-18-IT
(EUCTR)
01/12/200811/12/2008Effects of cardioprotective therapy, carvedilol vs ramipril, in patients affected by Duchenne and Becker muscular dystrophy. Clinical significance and prognostic value of Cardiac Magnetic Resonance study. - NDEffects of cardioprotective therapy, carvedilol vs ramipril, in patients affected by Duchenne and Becker muscular dystrophy. Clinical significance and prognostic value of Cardiac Magnetic Resonance study. - ND Duchenne and Becher muscular dystrophy
MedDRA version: 9.1;Level: LLT;Classification code 10013801;Term: Duchenne muscular dystrophy
Trade Name: DILATREND
INN or Proposed INN: Carvedilol
Trade Name: TRIATEC
INN or Proposed INN: Ramipril
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLINULLNot RecruitingFemale: no
Male: yes
Italy
2NCT00819845
(ClinicalTrials.gov)
December 20088/1/2009Ramipril Versus Carvedilol in Duchenne and Becker PatientsEffects of Cardioprotective Therapy, Carvedilol vs Ramipril, in Patients Affected by Duchenne and Becker Muscular Dystrophy. Clinical Significance and Prognostic Value of Cardiac Magnetic Resonance Study.Duchenne Muscular Dystrophy;Becker Muscular DystrophyDrug: carvedilol;Drug: ramiprilCatholic University, ItalyNULLRecruiting2 Years45 YearsMale194Phase 4Italy
3NCT00606775
(ClinicalTrials.gov)
December 200722/1/2008The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular DystrophyCarvedilol for the Prevention of Minor Cardiac Damage and Cardiac Function in Duchenne Muscular DystrophyDuchenne Muscular Dystrophy;CardiomyopathiesDrug: CarvedilolSuzuka HospitalNagoya UniversityRecruiting8 Years45 YearsMale60Phase 4Japan
4EUCTR2006-003075-12-IE
(EUCTR)
13/07/2006Effect of carvedilol on left ventricular systolic and diastolic function and the neurohormonal axis in patients with Duchenne muscular dystrophy and left ventricular dysfunction.Effect of carvedilol on left ventricular systolic and diastolic function and the neurohormonal axis in patients with Duchenne muscular dystrophy and left ventricular dysfunction. Duchenne muscular dystrophy is an X-linked inherited disorder which primarily affects skeletal muscle through a mutation in dystrophin which maps to the long arm of the X chromosome (Xp21). Patients with skeletal myopathy such as DMD eventually progress to develop dilated cardiomyopathy as dystrophin is expressed in all forms of muscle including cardiac and smooth muscle. Often the cause of death in patients with DMD is cardiac failure and arrhythmia.Trade Name: Eucardic
Product Name: Eucardic
Product Code: No code
INN or Proposed INN: CARVEDILOL
Department Of Paediatric CardiologyNULLNAFemale: yes
Male: yes
30Phase 4Ireland

210. 単心室症


臨床試験数 : 51 薬物数 : 53 - (DrugBank : 22) / 標的遺伝子数 : 32 - 標的パスウェイ数 : 67
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02946892
(ClinicalTrials.gov)
November 201623/9/2016Effect of Carvedilol on Exercise Performance in Fontan PatientsEffect of Carvedilol on Exercise Performance in Fontan PatientsSingle Ventricle;FontanDrug: Carvedilol;Drug: PlaceboUniversity of Texas Southwestern Medical CenterAmerican Heart AssociationCompleted10 Years35 YearsAll26Phase 4United States